A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

Trial Details

NCT ID
NCT06581406
Phase
PHASE2 / PHASE3
Sponsor
Replimune, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • RP2
  • Ipilimumab
  • Nivolumab
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • La Jolla, California, United States|32.84727,-117.2742
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • Patients who are 18 years of age or older at the time of signed informed consent.
  • Patients with confirmed diagnosis of metastatic Uveal melanoma not amenable to surgical resection.
  • Has at least 1 measurable and injectable tumor of ≥ 1 cm in longest diameter (≥ 1.5 cm in the shortest axis for a lymph node \[LN\]) that is amenab…
  • Must be willing to provide tumor biopsy samples.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →